Dr. Nathalie Johnson Calls for Medical Community to Move to Action for Equality in Genomic Testing for Black Women

Dr. Nathalie McDowell Johnson, M.D., FACS, surgical oncologist and immediate past president of the American Society of Breast Surgeons shares her opinion in STAT News article on why Black women with breast cancer experience higher death rates and how utilizing a more advanced genomic test can provide a more comprehensive understanding and accurate risk evaluation.

Read the Article
2023-09-25T13:12:44-07:00September 25th, 2023|Articles|

HIT Consultant: Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Nathalie Johnson, MD, FACS, President of The American Society of Breast Cancer Surgeons, recently spoke with HIT Consultant about why the conventional genomic test commonly used for breast cancer treatment planning is failing Black women, and in part, contributing to their disproportionately high mortality rate. Dr. Johnson discusses why MammaPrint provides more consistent results for Black women than the other gene expression profiling test, enabling more personalized treatment and improved outcomes.

Read the Article
2023-06-14T07:48:08-07:00March 30th, 2023|Articles|

Fierce Healthcare: Biden’s ‘Cancer Moonshot’ is already being fueled by tech addressing breast cancer

Fierce Healthcare recently spoke with Nathalie Johnson, MD, FACS, President of The American Society of Breast Cancer Surgeons, about the need for more widespread use of advanced gene expression profiling tests that provide more consistent results for Black women with early-stage breast cancer. Dr. Johnson highlights how the standard of care today negatively impacts outcomes for Black women, and why it is essential for clinicians to switch to more sophisticated, unbiased tests, such as MammaPrint & BluePrint, to address key disparities in breast cancer care.

Read the Article
2023-06-18T21:19:45-07:00March 22nd, 2023|Articles|
Go to Top